NCT04485663

A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Subcutaneously Administered ALG-010133 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Doses (Part 1) and Multiple Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Aligos Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

A Randomized Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Conditions

• Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	ALG-010133	Single or multiple doses of ALG-010133
DRUG	Placebo	Single or multiple doses of Placebo

Timeline

• Start date: 2020-08-17
• Primary completion: 2022-03-08
• Completion: 2022-03-08
• First posted: 2020-07-24
• Last updated: 2022-03-15

Locations

10 sites across 6 countries: China, Hong Kong, Moldova, New Zealand, South Korea, United Kingdom